Genmab A GMAB
NASDAQ GMAB
$39.81 +0.24 (+0.62%)
As of: Oct 22, 2026 · 10:13 AM EDT

Genmab A (GMAB) Change in Receivables (2023 - 2026)

Updated

Genmab A (GMAB) posted Change in Receivables of -$259 million for the quarter ended Jun 30, 2026.

Analysis

Genmab A (GMAB) Change in Receivables (2023 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Change in Receivables at Genmab A was -$302 million; for the year ended Dec 31, 2025, it was -$166 million.

  • In prior years, Genmab A's Change in Receivables was -$230 million in the year ended Dec 31, 2024, $116 million in the year ended Dec 31, 2023 and -$277 million in the year ended Dec 31, 2022.
  • The figure for the quarter ended Jun 30, 2026 stands as the lowest quarterly Change in Receivables since the quarter ended Dec 31, 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change Receivables (Qtr)
1 Eli Lilly 1,164.86 Bn 1,133.45 Bn 19.71 Bn -
2 Johnson & Johnson 632.18 Bn 550.71 Bn 17.26 Bn 1.35 Bn
3 AbbVie 503.53 Bn 476.64 Bn 12.70 Bn 1.37 Bn
4 Merck 378.03 Bn 332.41 Bn 12.21 Bn -
5 Novartis Ag 303.09 Bn 267.08 Bn 11.24 Bn -
6 Astrazeneca 266.38 Bn 240.07 Bn 12.86 Bn -
7 Amgen 241.24 Bn 196.64 Bn 7.24 Bn 1.09 Bn
8 Gilead Sciences 193.68 Bn 167.88 Bn 6.22 Bn 333.00 Mn
9 Pfizer 172.22 Bn 118.87 Bn 10.94 Bn -
10 Genmab A 2.58 Bn -2.80 Bn 1.07 Bn -57.00 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -57.00 Mn
Mar 31, 2026 158.00 Mn
Mar 31, 2025 124.00 Mn
Mar 31, 2024 39.00 Mn
Dec 31, 2023 -846.00 Mn
API Access

Genmab A Change in Receivables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=change-in-receivables&ticker=GMAB&period=max&api_key=YOUR_API_KEY